Stock Taper
SCREENER COMPARE ANY 2 STOCKS
QTTB
Q32 BIO INC.
NASDAQ
$15.03
▼ DOWN 6.93% (-1.12)

KEY STATISTICS

Market Cap$447.35 M
52w High$23.57
52w Low$1.62
Dividend Yield—
Frequency—
P/E7.26
Volume353.14K
Shares Out.29.76M

COMPANY

LEADERSHIP

Jodie Pope Morrison
CHIEF EXECUTIVE
Jodie Pope Morrison

COMPENSATION 2026

Salary$645,600
Stock Awards$335,280
Incentive Plan Pay$355,080
All Other Comp.$2,118
Total$1,558,870

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 28, 2018
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
22

PRICE TARGET

Target High$66.00
Target Low$14.00
Target Median$36.00
Target Consensus$38.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU

SPLIT RECORD

DATETYPERATIO
2024-03-26Reverse1:18

PRICE

$15.03 ▼ DOWN 6.93% (−$1.12)
OVERLAYS
$15.20$15.60$16.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM15.03

About Q32 Bio Inc.

https://www.q32bio.com ↗

Q32 Bio Inc. is a Waltham-based biotech company developing immunomodulatory biologics like ADX-097 and Bempikibart for autoimmune and inflammatory diseases, with products in Phase I and II trials.

INDUSTRY

Biotechnology

A PRODUCT Q32 BIO INC. IS KNOWN FOR

Bempikibart (ADX-914)
Bempikibart (ADX-914)

Bempikibart, Q32 Bio's lead Phase 2 antibody, aims to treat autoimmune diseases like alopecia areata by re-regulating adaptive immune function.

COMPETITORS

COMPETITOR
ABBV COMPARE
LLY COMPARE
PFE COMPARE
REGN COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
23
LISTED HERE
7
RANKED BY POSITION SIZE
VTS.AX
0.00% · 2.1M
AVUV
0.03% · 505.8K
FDM
0.27% · 45.4K
IWC
0.03% · 29.9K
DFAS
0.00% · 14.7K
QQQS
0.71% · 10.1K
TNXT
0.09% · 1.1K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
32.15%
HOLDERS
72
TOP 12 OF 72 · RANKED BY POSITION SIZE
Orbimed Advisors LLC
2.3M sh · $4.46M
Atlas Venture Life Science Advisors, LLC
2.1M sh · $6.95M
Opaleye Management Inc.
1.3M sh · $8.06M
Carlyle Group Inc.
1.1M sh · $7.08M
Acorn Capital Advisors, LLC
803.4K sh · $1.59M
Blackrock Inc.
342.3K sh · $6.14M
Vanguard Group Inc
321.1K sh · $1.07M
Arch Venture Management, LLC
320.5K sh · $2.06M
Monaco Asset Management Sam
311.1K sh · $616.05K
Pfizer Inc
277.8K sh · $922.22K
Mackenzie Financial Corp
246.3K sh · $1.58M
Sanofi
244.1K sh · $810.36K

RATINGS SNAPSHOT

Overall rating: A

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity5
Return On Assets5
Debt To Equity4
Price To Earnings3
Price To Book3
Overall Score4

INSIDER TRADES

★
DIRECTOR, OFFICER: CEO
Morrison Jodie Pope
Sale · 9.8K shares
2026-08-25
★
OFFICER: CFO AND PRESIDENT
Kalowski Lee
Sale · 4.0K shares
2026-08-25
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Violette Shelia M.
Sale · 2.8K shares
2026-08-25
★
DIRECTOR
Lundberg Sven Ante
Purchase · 10.8K shares
2026-06-12

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
OUTPERFORM 1
OVERWEIGHT 1
3 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Oppenheimer OUTPERFORM Wells Fargo OVERWEIGHT

SECTORS PEERS

PEERPRICE
SABS$3.79COMPARE
ANTX$5.58COMPARE
VRCA$5.69COMPARE
BOLD$2.83COMPARE
NXTC$6.09COMPARE
INTS$4.25COMPARE